Multiple myeloma - combination treatment with carfilzomib and dexamethasone

Active Ingredient: Isatuximab

Indication for Isatuximab

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Isatuximab is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

For this indication, competent medicine agencies globally authorize below treatments:

10 mg/kg body weight weekly during cycle 1 and every 2 weeks during cycle 2 and beyond

For:

Dosage regimens

Intravenous, 10 milligrams isatuximab per kilogram of body weight, once weekly, 4 doses in total, over the duration of 28 days. Afterwards, intravenous, 10 milligrams isatuximab per kilogram of body weight, once every 2 weeks.

Detailed description

The recommended dose of isatuximab is 10 mg/kg body weight administered as an intravenous infusion in combination with carfilzomib and dexamethasone (Isa-Kd).

Isatuximab dosing schedule in combination with carfilzomib and dexamethasone:

CyclesDosing schedule
Cycle 1 (28-day cycle)Days 1, 8, 15 and 22 (weekly)
Cycle 2 and beyond (28-day cycle)Days 1, 15 (every 2 weeks)

Each treatment cycle consists of a 28-day period. Treatment is repeated until disease progression or unacceptable toxicity.

Missed dose

The administration schedule must be carefully followed. If a planned dose of isatuximab is missed, administer the dose as soon as possible and adjust the treatment schedule accordingly, maintaining the treatment interval.

Dose adjustments

No dose reduction of isatuximab is recommended.

Administration adjustments should be made if patients experience infusion reactions, or in case of Grade 3 or 4 neutropenia, or febrile neutropenia and/or neutropenic infection.

For other medicinal products that are administered with isatuximab, the respective current summary of product characteristics should be considered.

Active ingredient

Isatuximab

Isatuximab is an IgG1-derived monoclonal antibody that binds to CD38 expressed on the surface of hematopoietic and tumor cells, including multiple myeloma cells. Isatuximab induces apoptosis of tumor cells and activation of immune effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC). It is used in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM).

Read more about Isatuximab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.